Ticker >

Unichem Lab share price

Unichem Laboratories Ltd.

NSE: UNICHEMLAB BSE: 506690 SECTOR: Pharmaceuticals & Drugs  26k   34   5

591.40
+15.40 (2.67%)
NSE: 24 Apr 04:11 PM

Price Summary

Today's High

₹ 599.95

Today's Low

₹ 577.95

52 Week High

₹ 607.4

52 Week Low

₹ 366.4

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

4163.8 Cr.

Enterprise Value

4108.19 Cr.

No. of Shares

7.04 Cr.

P/E

0

P/B

1.73

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  341.84

CASH

157.28 Cr.

DEBT

101.68 Cr.

Promoter Holding

70.22 %

EPS (TTM)

₹  -17.19

Sales Growth

13.73%

ROE

-11.91 %

ROCE

-10.21%

Profit Growth

-440.69 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year13.73%
3 Year5.84%
5 Year9.99%

Profit Growth

1 Year-440.69%
3 Year-249.21%
5 Year-165.13%

ROE%

1 Year-11.91%
3 Year-3.98%
5 Year-2.76%

ROCE %

1 Year-10.21%
3 Year-3.6%
5 Year-2.77%

Debt/Equity

0.0429

Price to Cash Flow

-35.49

Interest Cover Ratio

-28.7530649666318

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 70.22 0
Dec 2023 70.22 0
Sep 2023 70.21 0
Jun 2023 50.93 0
Mar 2023 50.93 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy liquidity position with current ratio of 3.32619969587893.
  • The company has a high promoter holding of 70.22%.

 Limitations

  • The company has shown a poor profit growth of -249.207234497145% for the Past 3 years.
  • The company has shown a poor revenue growth of 5.84321000954251% for the Past 3 years.
  • Company has a poor ROE of -3.98374481072339% over the past 3 years.
  • Company has a poor ROCE of -3.59727328552952% over the past 3 years
  • Company has negative cash flow from operations of -117.3297.
  • Tax rate is low at -7.38551082322278.
  • The company has a low EBITDA margin of -4.2178929961595% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 108.356.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 251.95 310.06 346.67 333.83 362.43
Total Expenditure 294.11 318.8 338.36 341.14 343.11
Operating Profit -42.16 -8.73 8.31 -7.31 19.32
Other Income 15.43 3.79 5.83 7.58 9.94
Interest 1.76 2.93 2.48 3.83 2.36
Depreciation 28.64 28.32 27.36 27.26 25.62
Exceptional Items 0 -107.64 0 0 68.02
Profit Before Tax -57.12 -143.84 -15.7 -30.81 69.3
Tax 0 0 0 0 0
Profit After Tax -57.12 -143.84 -15.7 -30.81 69.3
Adjusted EPS (Rs) -8.11 -20.43 -2.23 -4.38 9.84

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 967.74 904.44 1123.97 942.93 1072.43
Total Expenditure 1028.53 995.05 1028.51 986.48 1165.35
Operating Profit -60.79 -90.61 95.47 -43.55 -92.91
Other Income 101.54 99.17 47.37 42.07 41.85
Interest 0.62 1.28 1.3 2.07 9.38
Depreciation 61.71 71.09 75.89 83.19 105.98
Exceptional Items 0 0 0 0 -112.66
Profit Before Tax -21.58 -63.81 65.65 -86.75 -279.09
Tax -28.62 -7.5 11.56 -31.32 20.61
Net Profit 8.8 -56.32 54.08 -55.43 -299.7
Adjusted EPS (Rs.) 1 -8 7.68 -7.87 -42.57

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 14.08 14.08 14.08 14.08 14.08
Total Reserves 2717.86 2633.1 2683.25 2657.96 2370.19
Borrowings 0 0 0 89.01 63.65
Other N/C liabilities 26.79 29.68 50.27 50.62 49.56
Current liabilities 271.5 348.27 371.45 310.42 388.66
Total Liabilities 3030.22 3025.13 3119.06 3122.08 2886.14
Assets
Net Block 785.16 824.94 846.23 963.12 1235.94
Capital WIP 90.25 330.84 567.73 494.18 147.82
Intangible WIP 0 0 0 0 0
Investments 241.7 249.17 283.99 126.22 38.98
Loans & Advances 56.36 111.88 112.21 164.61 167.22
Other N/C Assets 4.53 3.6 3.53 3.47 3.41
Current Assets 1852.23 1504.71 1305.37 1370.49 1292.76
Total Assets 3030.22 3025.13 3119.06 3122.08 2886.14
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations -19.11 -63.81 65.65 -86.75 -279.09
Adjustment -7.08 -6.17 49.68 72.2 203.3
Changes in Assets & Liabilities -217.91 25.49 -147.63 -147.82 -41.45
Tax Paid -7.2 2.65 -0.31 4.06 -0.09
Operating Cash Flow -251.3 -41.84 -32.61 -158.31 -117.33
Investing Cash Flow -175.46 77.28 -72.79 104.03 240.63
Financing Cash Flow -44.89 -21.02 -45.07 95.8 -61.76
Net Cash Flow -471.65 14.42 -150.48 41.53 61.54

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 50.93 50.93 70.21 70.22 70.22
anita prakash mody 1.88 1.88 1.88 1.88 1.88
dr. prakash amrut mody 46.16 46.16 12.78 12.78 12.78
dr. prakash amrut mody - ... 0.06 0.06 0.06 0.06 0.06
dr. prakash amrut mody - ... 0.07 0.07 0.07 0.07 0.07
dr. prakash amrut mody - ... 0.06 0.06 0.06 0.06 0.06
ipca laboratories limited... - - 52.65 52.67 52.67
suparna prakash mody 1.35 1.35 1.35 1.35 1.35
supriya prakash mody 1.35 1.35 1.35 1.35 1.35
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 49.07 49.07 29.79 29.78 29.78
dsp healthcare fund - - - 1.04 1.04
hdfc small cap fund 6.69 6.09 7.71 7.95 7.97
investor education and pr... - 0.97 - - 0.97
llp 1.32 0.89 0.02 0.03 0.02
investor education and pr... 0.93 - 0.97 0.97 -
krishnaraj venkataraman 1.02 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Unichem Laboratories informs about closure of trading window 26 Mar 2024, 4:53PM Unichem Laboratories informs about results of postal ballot and scrutinizer’s report23 Mar 2024, 11:20AM Unichem Laboratories informs about press release22 Feb 2024, 1:58PM Unichem Laboratories informs about postal ballot notice21 Feb 2024, 9:43AM Unichem Lab - Quaterly Results5 Feb 2024, 2:19PM Unichem Lab - Quaterly Results5 Feb 2024, 2:19PM Unichem Lab - Quaterly Results5 Feb 2024, 2:19PM Unichem Laboratories gets ANDA approval for Doxazosin tablets11 Jan 2024, 12:26PM Unichem Laboratories informs about certificate9 Jan 2024, 11:58AM Unichem Laboratories sells balance stake in Optimus Drugs5 Dec 2023, 11:18AM Unichem Lab - Quaterly Results1 Nov 2023, 1:20PM Unichem Lab - Quaterly Results1 Nov 2023, 1:20PM Unichem Laboratories gets ANDA approval for Prasugrel Tablets 30 Aug 2023, 9:58AM Unichem Laboratories informs about press release23 Aug 2023, 4:30PM Unichem Laboratories informs about AGM22 Aug 2023, 10:02AM CCI approves acquisition of up to 59.38% stake of Unichem Laboratories by Ipca28 Jul 2023, 11:07AM Unichem Laboratories’ consolidated net loss narrows to Rs 0.66 crore in Q1 14 Jul 2023, 3:30PM Unichem Lab - Quaterly Results14 Jul 2023, 2:46PM Unichem Lab - Quaterly Results14 Jul 2023, 2:46PM Unichem Lab - Quaterly Results14 Jul 2023, 2:46PM Unichem Laboratories informs about appointment of chairman cum MD26 Jun 2023, 12:11PM Unichem Lab - Quaterly Results23 May 2023, 1:34PM Unichem Lab - Quaterly Results23 May 2023, 1:34PM Unichem Lab - Quaterly Results23 May 2023, 1:34PM Unichem Laboratories informs about details of loss of certificate19 Apr 2023, 12:13PM Unichem Laboratories informs about compliance certificate12 Apr 2023, 12:40PM Unichem Laboratories informs about press release4 Apr 2023, 2:03PM Unichem Laboratories informs about update on postal ballot notice4 Apr 2023, 11:40AM Unichem Laboratories informs about postal ballot notice3 Apr 2023, 12:31PM Unichem Laboratories informs about board of director’s update20 Mar 2023, 4:33PM Unichem Laboratories gets ANDA approval for Ranolazine Extended-Release Tablets17 Mar 2023, 12:27PM Unichem Laboratories reports consolidated net loss of Rs 63.92 crore in Q3 7 Feb 2023, 3:17PM Unichem Lab - Quaterly Results6 Feb 2023, 1:45PM Unichem Lab - Quaterly Results6 Feb 2023, 1:45PM Unichem Lab - Quaterly Results6 Feb 2023, 1:45PM Unichem Laboratories informs about newspaper advertisement13 Jan 2023, 3:11PM Unichem Laboratories informs about issuance of duplicate share certificate 23 Nov 2022, 9:44AM Unichem Lab - Quaterly Results11 Nov 2022, 1:24PM Unichem Lab - Quaterly Results11 Nov 2022, 1:24PM Unichem Laboratories gets ANDA approval for Extended Phenytoin Sodium Capsules14 Oct 2022, 3:11PM Unichem Laboratories informs about press release14 Oct 2022, 12:30PM Unichem Laboratories’ arm recalls 18,960 bottles of hypertension drug in US6 Oct 2022, 11:07AM Unichem Laboratories completes sale of 19.97% equity shares in Optimus26 Sep 2022, 9:50AM Unichem Laboratories informs about credit rating19 Sep 2022, 4:32PM Unichem Laboratories informs about press release23 Aug 2022, 12:41PM Unichem Laboratories gets ANDA nod for Carbamazepine Tablets23 Aug 2022, 11:30AM Unichem Laboratories gets ANDA approval for Quetiapine Extended-Release Tablets16 Aug 2022, 12:40PM Unichem Laboratories gets ANDA nod for Labetalol Hydrochloride tablets10 Aug 2022, 9:29AM Unichem Laboratories informs about outcome of board meeting9 Aug 2022, 3:17PM Unichem Lab - Quaterly Results9 Aug 2022, 1:24PM

Unichem Lab Stock Price Analysis and Quick Research Report. Is Unichem Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Unichem Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Unichem Lab cash from the operating activity was Rs -117.3297 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Unichem Lab has a Debt to Equity ratio of 0.0429 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Unichem Lab , the EPS growth was -440.686405263626 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Unichem Lab has OPM of -8.66380177693284 % which is a bad sign for profitability.
     
  • ROE: Unichem Lab have a poor ROE of -11.9080820299937 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Unichem Lab is Rs 591.4. One can use valuation calculators of ticker to know if Unichem Lab share price is undervalued or overvalued.
Last Updated on:
Brief about Unichem Lab

Unichem Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Unichem Laboratories Ltd. is a leading pharmaceutical company that specializes in the manufacturing and marketing of generic pharmaceuticals. With a strong presence in domestic and international markets, Unichem has established itself as a trusted name in the healthcare sector. The company was founded in 1944 and has since grown to become one of the key players in the pharmaceutical industry.

Share Price Analysis - Unichem Laboratories Ltd.

Unichem Laboratories Ltd.'s share price is an important parameter for investors looking to assess the company's performance in the stock market. Our pre-built screening tools provide an in-depth analysis of the company's share price history, enabling long-term investors to make informed decisions. The share price is influenced by various factors, including market trends, company performance, and industry outlook.

Balance Sheet Analysis - Unichem Laboratories Ltd.

Unichem Laboratories Ltd.'s balance sheet is a key financial statement that provides insights into the company's financial health. Our premium features, such as our fair value calculation tools, including DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, assist investors in evaluating the company's balance sheet. This allows investors to assess the company's financial stability and make informed investment decisions.

Annual Report - Unichem Laboratories Ltd.

The annual report of Unichem Laboratories Ltd. is a comprehensive document that provides a detailed overview of the company's performance and financial statements for the fiscal year. Investors can download the annual reports from our website to gain a deeper understanding of the company's strategies, operations, and future prospects.

Dividend Analysis - Unichem Laboratories Ltd.

Dividends are an important aspect for long-term investors. Unichem Laboratories Ltd. provides regular dividend payouts to its shareholders. By analyzing the company's dividend history, investors can assess the company's dividend policy, sustainability, and potential growth. Our pre-built screening tools help investors track dividend payouts and make informed investment decisions.

Quarterly Result Analysis - Unichem Laboratories Ltd.

Unichem Laboratories Ltd.'s quarterly results provide a snapshot of the company's financial performance during a specific period. Investors can download the quarterly results from our website to analyze key financial metrics and assess the company's growth trajectory. Our premium features, such as fair value calculation tools, provide an in-depth analysis of the quarterly results, allowing investors to evaluate the company's financial performance.

Stock Price Analysis - Unichem Laboratories Ltd.

Unichem Laboratories Ltd.'s stock price is determined by various factors, including market dynamics, investor sentiment, and company-specific factors. Our pre-built screening tools provide an analysis of the company's stock price history, allowing investors to identify trends and patterns. This analysis helps long-term investors gain insights into the company's stock price and make informed investment decisions.

Price Chart Analysis - Unichem Laboratories Ltd.

The price chart of Unichem Laboratories Ltd. provides an overview of the company's stock price movement over a specific period. Our pre-built screening tools offer interactive price charts that help investors track the company's stock price performance, identify support and resistance levels, and analyze trends. This analysis assists long-term investors in understanding the stock's historical performance and making informed investment decisions.

News and Updates - Unichem Laboratories Ltd.

Staying updated with the latest news and updates about Unichem Laboratories Ltd. is crucial for investors. Our website provides curated news articles, press releases, and market updates related to the company. These resources help investors stay informed about key developments, industry trends, and regulatory changes that may impact the company's performance.

Conference Call Transcripts - Unichem Laboratories Ltd.

Conference call transcripts provide insights into the discussions and decisions made during the company's quarterly or annual conference calls. Investors can download the conference call transcripts from our website to gain a deeper understanding of management's perspective on the company's performance, growth strategy, and future outlook. These transcripts serve as valuable resources for long-term investors looking for a comprehensive analysis.

Investor Presentations - Unichem Laboratories Ltd.

Investor presentations offered by Unichem Laboratories Ltd. provide a detailed overview of the company's business model, growth strategy, financial performance, and future outlook. Investors can download these presentations from our website to gain insights directly from the company. These presentations help investors understand the company's value proposition, innovative initiatives, and competitive advantage in the pharmaceutical industry.

Promoters and Shareholders - Unichem Laboratories Ltd.

Unichem Laboratories Ltd.'s promoters and shareholders play a crucial role in shaping the company's operations and growth. Our website provides information about the company's promoters and major shareholders, helping investors gain insights into the management's expertise, experience, and long-term vision. This information is valuable for investors looking to assess the credibility and stability of the company's ownership structure.

In conclusion, Unichem Laboratories Ltd. offers a comprehensive stock analysis page that caters to the needs of long-term stock investors. With a focus on providing relevant and accurate information, our website equips investors with the necessary tools to analyze the company's performance and make informed investment decisions. Our pre-built screening tools and premium features, such as fair value calculation tools, provide investors with valuable insights into various aspects of Unichem Laboratories Ltd.'s stock. Downloadable resources, including annual reports, conference call transcripts, and investor presentations, enable investors to delve deeper into the company's strategies and future prospects. Stay updated with the latest news and updates to stay informed about key developments in the pharmaceutical industry. Happy investing!

Read More
X